HR+ and HER2- Metastatic Breast Cancer
Professor Hilary Martin discusses HR+ and HER2- metastatic breast cancer
HR+ and HER2- Metastatic Breast Cancer Read More »
Enhance Understanding of Novel Therapeutics for Breast Cancer
Join Dr. Nick Zdenkowski for an insightful commentary on breast cancer therapeutics. He will cover the latest clinical trial results and emerging therapies, including CDK4/6 inhibitors, antibody-drug conjugates (ADCs), endocrine therapy, and PARP inhibitors. Dr. Zdenkowski will discuss the mechanisms of action, efficacy, and safety profiles of these treatments.
Enhance Understanding of Novel Therapeutics for Breast Cancer Read More »
Independent highlights of American Society of Clinical Oncology (ASCO) 2025
COMING SOON! Video highlights from the American Society of Clinical Oncology (ASCO) 2025, taking place in Chicago, IL from May 30 – June 3, 2025. These clips will provide invaluable insights and updates on Breast Cancer research from ASCO 2025.
Independent highlights of American Society of Clinical Oncology (ASCO) 2025 Read More »
Comprehensive Pain Management: The Role of the Multidisciplinary Team, Shared Decision-Making, and Patient Access
Dr. Danusha Sabanathan gives a comprehensive overview of pain management, emphasizing the importance of a multidisciplinary approach, shared decision-making, patient education, and addressing barriers to accessing pain management resources.
Early stage high risk ER+/HER2- Breast Cancer
Dr. Nick Zdenkowski discusses a case of early-stage, high-risk breast cancer, detailing the patient’s diagnosis, treatment plan, and outcomes.
Early stage high risk ER+/HER2- Breast Cancer Read More »
December 13 – Dr. Nicholas Zdenkowski
Dr. Nick Zdenkowski discusses tumor-infiltrating lymphocytes as prognostic and predictive factors in breast cancer.
December 13 – Dr. Nicholas Zdenkowski Read More »
December 13 – Dr. Virginia Kaklamani
Dr. Virginia Kaklamani discusses the PATINA trial, a phase III clinical trial.
December 13 – Dr. Virginia Kaklamani Read More »
December 13 – Dr. Nicholas Zdenkowski
Dr. Nick Zdenkowski discusses resistance mechanisms to CDK4/6 inhibitors.
December 13 – Dr. Nicholas Zdenkowski Read More »
December 13 – Dr. Virginia Kaklamani
Dr. Virginia Kaklamani highlights the EMBER-3 clinical trial, which found that imlunestrant outperformed single-agent endocrine therapy in patients with ESR1 mutations and showed improvement when combined with abemaciclib, suggesting potential FDA approval.
December 13 – Dr. Virginia Kaklamani Read More »
December 13 – Dr. Nicholas Zdenkowski
Dr. Nick Zdenkowski discusses the ZEST trial.
December 13 – Dr. Nicholas Zdenkowski Read More »